About Us
About AJMC
About AJPB
About EBO
About EBD
Publications
AJMC
AJPB
Evidence-Based Diabetes Management
Evidence-Based Oncology
Supplements
Subscribe for FREE
AJMC TV
Interviews
Peer Exchange
Interactive
Interactive Tools
Featured Podcasts
Conferences
ACC 2013
AJMC Live Meeting - Oncology
AES2012
AHIP 2012
AHIP 2012 Fall Forum
AHIP Medicare Medicaid
AMCP Fall 2012
AMCP Spring 2013
ADA 2012
ADA 2013
ASH 2012
CHEST 2012
Joslin Diabetes Innovation
NAMCP 2012
NAMCP Spring 2013
SCAI 2013
ATS 2013
ASCO 2013
ASHP Summer 2013
Sleep 2013
News
Info for Authors
Information for Authors
Call for Papers
Submit / Track a Manuscript
Authorship Forms
Information for Reviewers
Resource Centers
Acute Coronary Syndrome
Biosimilars
Care Management
Diabetes
Evidence-Based Oncology
Pain
Value-Based Cardiology
Value-Based Insurance Design
Advertisement
Supplement
How Far Have We Come in Treating Congestive Heart Failure?
Published Online:
July 01, 1998
Bertram Pitt, MD
Issue: New and Emerging Therapies in the Treatment of Hypertension and Congestive Heart Failure
SUPPLEMENT CONTENT
Participating Faculty
Introduction: Current Concepts in Hypertension Management and A Look Toward the Future
The Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure
Sheldon G. Sheps, MD; Henry R. Black, MD; Jerome D. Cohen, MD; Norman Kaplan, MD; Keith C. Ferdinand, MD
Gene Polymorphism Influences Response to Angiotensin Blockade
Gershan K. Davis, MD
New Drug Class Offers Benefits in Heart Failure
Edward P. Havranek, MD
Comparative Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blocking Agents on Left Ventricular Volumes in Elderly Patients with Heart Failure
Marvin A. Konstam, MD
Phase I Results of the Randomized Evaluation of Left Ventricular Dysfunction (RESOLVD) Trial
Salim Yusuf, DPhil
European Society of Cardiology: Angiotensin II Antagonists: Why is There So Much Excitement?
Norman K. Hollenberg, MD
What are the Pharmacological Differences Between Angiotensin II Antagonists
Thomas Unger, MD
Clinical Implications of Differences Between Angiotensin II Antagonists
Peter S. Sever, MD; Giuseppe Mancia, MD
Exploring the Benefits Beyond Blood Pressure Control
Hans Lithell, MD; Luis Ruilope, MD
How Far Have We Come in Treating Congestive Heart Failure?
Bertram Pitt, MD
Rationale for Angiotensin Receptor Blockers in Congestive Heart Failure
Alan H. Gradman, MD
Angiotensin Receptor Blockers: Cardio-renal Implications in Patients with Congestive Heart Failure
Dominic A. Sica, MD
Selected Abstracts
Bibliography
Click for Full Issue
Advertisement
More on AJMC.COM
No Result Found
Advertisement